Results from a small, independently funded, double-blind, active-comparator trial suggest that baricitinib could be beneficial in the treatment of lupus nephritis.
Although no increased cancer risk was seen vs methotrexate or placebo, Janus kinase inhibitors were associated with a higher cancer risk than were tumor necrosis factor inhibitors in a meta-analysis.
In the setting of cancer, cytokines contribute to cells’ antitumor response, cell damage, inflammation, angiogenesis, metastasis, and other cellular processes that enable tumor survival
The EMA has issued a positive opinion of the type II variation application of the JAK1 inhibitor filgotinib, based on testicular function safety data from two phase 2 clinical trials.
Abrocitinib shows consistent efficacy and safety in patients with moderate-to-severe atopic dermatitis, whether or not they ve already been treated with a biologic, researchers report.